Hugel to enter ECM-based injectable market with aesthetic portfolio expansion

Hugel secures the domestic sales rights for ECM-based injectable CellREDM, planning collaboration with Hans Biomed The company aims to create synergies with its botulinum toxin and dermal filler products as a new growth engine SEOUL, South Korea, March 31, 2026 /PRNewswire/ -- Hugel Inc.,...